Comparative assessment of nanomaterial definitions and safety evaluation considerations  by Boverhof, Darrell R. et al.
lable at ScienceDirect
Regulatory Toxicology and Pharmacology 73 (2015) 137e150Contents lists avaiRegulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate/yrtphComparative assessment of nanomaterial deﬁnitions and safety
evaluation considerations
Darrell R. Boverhof a, Christina M. Bramante b, John H. Butala c, Shaun F. Clancy d,
Mark Lafranconi e, Jay West f, *, Steve C. Gordon g
a The Dow Chemical Company, 200 Larkin, E-157, Midland, MI 48674, USA
b Cabot Corporation, 157 Concord Road, Billerica, MA 01821, USA
c Toxicology Consultants, Inc., 7 Glasgow Road, Gibsonia, 15044 PA, USA
d Evonik Corporation, 299 Jefferson Road, Parsippany, NJ 07054, USA
e Tox Horizons, LLC, 7569 Kings Mills Rd, Maineville, OH 45039, USA
f American Chemistry Council, 700 2nd Street NE, Washington, DC 20002, USA
g 3M Company, 3M Center, Building 220-6E-03, St. Paul, MN 55144, USAa r t i c l e i n f o
Article history:
Received 9 January 2015
Received in revised form
21 May 2015
Accepted 2 June 2015
Available online 23 June 2015
Keywords:
Nanomaterial
Deﬁnitions
Risk evaluation* Corresponding author. American Chemistry Co
Washington, DC 20002, USA.
E-mail addresses: rboverhof@dow.com (D.R. Bov
cabotcorp.com (C.M. Bramante), butala@jhbutala.com
evonik.com (S.F. Clancy), toxhorizons@gmail.com
americanchemistry.com (J. West), scgordon@mmm.co
http://dx.doi.org/10.1016/j.yrtph.2015.06.001
0273-2300/© 2015 The Authors. Published by Elseviera b s t r a c t
Nanomaterials continue to bring promising advances to science and technology. In concert have come
calls for increased regulatory oversight to ensure their appropriate identiﬁcation and evaluation, which
has led to extensive discussions about nanomaterial deﬁnitions. Numerous nanomaterial deﬁnitions have
been proposed by government, industry, and standards organizations. We conducted a comprehensive
comparative assessment of existing nanomaterial deﬁnitions put forward by governments to highlight
their similarities and differences. We found that the size limits used in different deﬁnitions were
inconsistent, as were considerations of other elements, including agglomerates and aggregates, distri-
butional thresholds, novel properties, and solubility. Other important differences included consideration
of number size distributions versus weight distributions and natural versus intentionally-manufactured
materials. Overall, the deﬁnitions we compared were not in alignment, which may lead to inconsistent
identiﬁcation and evaluation of nanomaterials and could have adverse impacts on commerce and public
perceptions of nanotechnology. We recommend a set of considerations that future discussions of
nanomaterial deﬁnitions should consider for describing materials and assessing their potential for health
and environmental impacts using risk-based approaches within existing assessment frameworks. Our
intent is to initiate a dialogue aimed at achieving greater clarity in identifying those nanomaterials that
may require additional evaluation, not to propose a formal deﬁnition.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Deﬁnitions of nanomaterials and their use in regulatory evalu-
ations have been, and continue to be, an area of active scientiﬁc and
policy debate (ICCA, 2010; Maynard, 2011; Stamm, 2011; Bleeker
et al., 2013). Nanomaterials may exhibit properties different from
their non-nano forms, and these different properties have raiseduncil, 700 2nd Street, NE,
erhof), christina.bramante@
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(M. Lafranconi), jay_west@
m (S.C. Gordon).
Inc. This is an open access article uquestions about potential human health and environmental risks.
The International Organization for Standardization (ISO) has
deﬁned “nanomaterial” as a “material with any external dimension
in the nanoscale or having internal structure or surface structure in
the nanoscale” (ISO, 2010) and “nanoparticle” as a “nano-object
with all three external dimensions in the nanoscale” where nano-
scale is deﬁned as the size range from approximately 1e100 nm
(ISO, 2008). These technical deﬁnitions, based on size only, may be
insufﬁcient from a risk evaluation standpoint because they do not
include other important elements that should be considered when
determining whether a nanomaterial may need additional review.
Discussions about developing a deﬁnition for nanomaterials
have been challenging because of the need to satisfy two diverging
considerations. A deﬁnition should be broad enough to deﬁnender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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be so broad as to include those materials for which additional ex-
amination or evaluation would not be meaningful in terms of
protecting human health or the environment. A balance is neces-
sary to ensure appropriate allocation of resources to most effec-
tively protect the health and safety of humans and the
environment. Deﬁnitions proposed to date have taken a variety of
approaches in attempting to strike a suitable balance, but while
they may satisfy speciﬁc jurisdictional mandates, their frequently
contradictory inclusions and exclusions present a complex regu-
latory maze for producers of nanomaterials and products contain-
ing them. Difﬁculties associated with attempting to comply with
contradictory nanomaterial deﬁnitions and potential regulations
can impede international trade and, more fundamentally, reduce
public conﬁdence in the adequacy of regulatory protections.
Nanomaterials are neither inherently hazardous nor inherently
safe (Auffan et al., 2009; Donaldson and Poland, 2013), and it has
been broadly recognized that they should not be treated as such in
evaluation programs (SCENIHR, 2007; Holdren, 2011; Hamburg,
2012). Likewise, the informational elements of a nanomaterial
deﬁnition presented in this paper are not intended to identify
inherently hazardous or non-hazardous materials. Rather, they are
intended to be used in conjunction with available hazard and
exposure information to identify nanoscale materials whichmay be
of interest for potential priority setting, risk assessment, and risk
management activities. While the elements we identify in this
paper can help strengthen or inform developing deﬁnitions, they
should not be viewed as a comprehensive list of factors to be
considered in a safety assessment of nanomaterials. Regardless of
the deﬁnition that is applied, there is an obligation of both regu-
lators and the regulated community to ensure that a material is
evaluated appropriately to determine whether it poses a risk to
human health or the environment. This evaluation should be based
not only on the intrinsic hazard potential of the material but on
consideration of exposure potential (e.g. during manufacturing,
use, and disposal) as well.
The purpose of this paper is twofold: (1) to compare and
contrast existing nanomaterial deﬁnitions and (2) to present a set of
informational elements to be considered as discussions on the need
for deﬁnitions and nanomaterial regulatory frameworks continue.
The intent is not to propose a formal deﬁnition for nanomaterials,
but to initiate a dialogue aimed at achieving greater clarity in
identifying those nanomaterials that may require additional eval-
uation. That process should account for each of the elements pre-
sented in this paper at some point in the evaluation, while seeking
to eliminate differences that create further ambiguity. The ideas
expressed in this paper apply to the commercial manufacturing and
use of nanomaterials.2. Comparison/contrast of current deﬁnitions
Numerous deﬁnitions for nanomaterials have been proposed by
various government, industry, and standards organizations. These
deﬁnitions are often inconsistent in their elements and scope,
which can lead to confusion in determiningwhether amaterial is or
is not considered to be a “nanomaterial.” To better understand the
similarities and differences among deﬁnitions, we performed a
comprehensive comparative assessment of 14 deﬁnitions from
various regulatory authorities (Table 1). The assessment included
formal regulatory deﬁnitions as well as deﬁnitions stated in guid-
ance or policy documents (“advisory deﬁnitions” in Table 1). The
deﬁnitions are generally intended to address safety impacts to
people and the environment, though there may appear to be a
particular emphasis on human health impacts. The elementsconsidered in this analysis are applicable for human and environ-
mental safety, as well as toxicological and ecotoxicological effects.
Size (or external dimensions) was the only common element
across all of the deﬁnitions, though the upper size limits were
sometimes variable among the deﬁnitions. Several important core
elements that were not consistently mentioned included: consid-
eration of agglomerates and aggregates, distributional thresholds,
novel properties, and solubility. Other important differences
included number size distributions versus weight distributions and
the inclusion of natural and incidental nanomaterials along with
those manufactured intentionally. A summary of these core ele-
ments and the similarities and differences among the 14 deﬁnitions
is presented in Table 2. This comparative assessment highlights
some of the key differences that can lead to a lack of clarity and
consistency with respect to the term “nanomaterial” and what
materials may be subject to existing or developing regulations.
What follows is a discussion on some of the factors that should be
considered when developing regulatory deﬁnitions or identifying
nanomaterials that may be of interest, with a focus on those ele-
ments identiﬁed through the comparative assessment in Table 2.3. Core elements for describing nanomaterials
3.1. Size
Size is the fundamental deﬁning characteristic of all nano-
materials. While size is an easy concept to understand, it is more
difﬁcult to apply because there are no natural physical or chemical
boundaries that delineate the “nanoscale.” By convention,
1e100 nm is the size range most commonly used in reference to
nanomaterials, but there is no bright line that clearly demarks the
nanoscale from a chemical or biological perspective. At the lower
end of the range, 1 nm is intended to distinguish between indi-
vidual molecules and nanomaterials, although some molecules
(e.g., some proteins and biomolecules) may have at least one
dimension larger than 1 nm. Many nanomaterial deﬁnitions
explicitly include materials that may have dimensions below 1 nm
(e.g., fullerenes and graphene; Table 2). At this lower end of
“nanoscale,” the characteristics and properties of the material are
largely deﬁned by the chemistry of the molecule and not by the
physical nature of the formed nanoscale materials.
The upper end of the “nanoscale” at 100 nm is an arbitrary cut-
off since the size-dependent behavior of materials does not stop or
begin abruptly at 100 nm. Many properties characteristic of the
nanoscale, such as solubility, light scattering, and surface area ef-
fects, are predictable and continuous characteristics of the bulk
materials (Donaldson and Poland, 2013). In an attempt to be in-
clusive of all the characteristics that may be important for regula-
tory oversight, some authorities have expanded the upper range of
the nanoscale well beyond 100 nm (Table 2) (Health Canada, 2011;
US FDA, 2011; Taiwan, 2012).
While size limits are somewhat arbitrary, there is general
agreement that any unique nano-speciﬁc phenomena of particu-
lates are most likely to occur between 1 and 100 nm. For instance,
the properties of inorganic particles were evaluated by Auffan et al.
(2009) who found that novel, size-dependent properties of nano-
scale materials, such as catalytic properties of gold, the photo-
catalytic activity of TiO2, and the tunable ﬂuorescent behavior of
quantum dots, occur below 30 nm (see the Novel Properties section
of this paper for further discussion). Most regulatory authorities
have used 1e100 nm to deﬁne the nanoscale, which is consistent
with the ISO standard (ISO, 2008). We agree that this provides a
reasonable range, provided there is recognition that particle size
alone is not sufﬁcient for the evaluation of a nanomaterial and that
Table 1
Current regulatory and advisory deﬁnitions of “nanomaterial”.
Organization Deﬁnition Product category Status
European Commission
Cosmetics Directive
(EC, 2009)
“ ‘[N]anomaterial’ means an insoluble or biopersistant and intentionally
manufactured material with one or more external dimensions, or an
internal structure, on the scale from 1 to 100 nm.”
Cosmetics Regulatory Deﬁnition
Australian Government
Department of Health
and Ageing (NICNAS, 2010)
“[I]ndustrial materials intentionally produced, manufactured or engineered
to have unique properties or speciﬁc composition at the nanoscale, that is a
size range typically between 1 nm and 100 nm, and is either a nano-object
(i.e. that is conﬁned in one, two, or three dimensions at the nanoscale) or is
nanostructured (i.e. having an internal or surface structure at the nanoscale).
Aggregates and agglomerates are included and apply to materials where 10%
or more of the particles by number count meet the above deﬁnition.”
All non-food Advisory Deﬁnition
Health Canada
(Health-Canada, 2011)
Health Canada considers any manufactured substance or product and any
component material, ingredient, device, or structure to be nanomaterial if it
is at or within the nanoscale in at least one external dimension, or has internal
or surface structure at the nanoscale, or if it is smaller or larger than the
nanoscale in all dimensions and exhibits one or more nanoscale
properties/phenomena. Nanoscale properties/phenomena refer to properties
that are attributable to the size of the substance and size effects.
All Advisory Deﬁnition
United States Food and Drug
Administration (US FDA, 2011)
There is no formal agency deﬁnition. However, “when considering whether an
FDA-regulated product contains nanomaterials, or otherwise involves the
application of nanotechnology, FDA will ask: Whether an engineered material
or end product has at least one dimension in the nanoscale range (approximately
1 nm to 100 nm); or whether an engineered material or end product exhibits
properties or phenomena, including physical or chemical properties or biological
effects, that are attributable to its dimension(s), even if these dimensions fall
outside the nanoscale range, up to one micrometer.”
Cosmetics,
pharmaceuticals,
food, and food
contact
Advisory Deﬁnition
United States Environmental
Protection Agency (US EPA,
2007, 2011b, 2014)
There is no formal agency deﬁnition. However, the agency has outlined key criteria
across several documents, including: solid at 25 C and atmospheric pressure,
particle size between 1 and 100 nm in at least 1 dimension; the material exhibits
unique and novel properties because of its size; the material is engineered at the
nanoscale; inclusion of primary particles, aggregates and agglomerates; and a
distribution of particles with greater than 10% by weight less than 100 nm.
All except:
cosmetics,
pharmaceuticals,
food and food
contact
Advisory Deﬁnition
European Commission,
Recommendation on the
Deﬁnition of Nanomaterials
(EC, 2011a)
“ ‘Nanomaterial’ means a natural, incidental or manufactured material
containing particles, in an unbound state or as an aggregate or as an agglomerate
and where, for 50% or more of the particles in the number size distribution, one
or more external dimensions is in the size range 1 nme100 nm.”
“In speciﬁc cases and where warranted by concern for environment, health, safety
or competitiveness the number size distribution threshold of 50% may be replaced
by a threshold between 1 and 50%.”
“[F]ullerenes, graphene ﬂakes and single wall carbon nanotubes with one or more
external dimensions below 1 nm should be considered as nanomaterials.”
All Advisory Deﬁnition
European Parliament and the
Council of the European
Union on the provision
of food information to
consumers (EC, 2011b)
“’[E]ngineered nanomaterial’ means any intentionally produced material that has
one or more dimensions of the order of 100 nm or less or that is composed of discrete
functional parts, either internally or at the surface, many of which have one or more
dimensions of the order of 100 nm or less, including structures, agglomerates or
aggregates, which may have a size above the order of 100 nm but retain properties
that are characteristic of the nanoscale.
“Properties that are characteristic of the nanoscale include: (i) those related to the
large speciﬁc surface area of the materials considered; and/or (ii) speciﬁc
physico-chemical properties that are different from those of the non-nanoform of
the same material.”
Food Regulatory Deﬁnition
(continued on next page)
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Table 1 (continued )
Organization Deﬁnition Product category Status
European Commission,
Biocides Directive (EC, 2012)
“ ‘[N]anomaterial’ means a natural or manufactured active substance or non-active
substance containing particles, in an unbound state or as an aggregate or as an
agglomerate and where, for 50% or more of the particles in the number size
distribution, one or more external dimensions is in the size range 1e100 nm.
“Fullerenes, graphene ﬂakes, and single wall carbon nanotubes with one or more
external dimension below 1 nm shall be considered as nanomaterials.”
Biocides Regulatory Deﬁnition
French Ministry of Ecology,
Sustainable Development
and Energy (ANSES, 2012)
“Substance at nanoscale” is deﬁned as a substance “intentionally produced
at nanometric scale, containing particles, in an unbound state or as an aggregate
or as an agglomerate and where, for a minimum of 50% of particles in the number
size distribution, one or more external dimensions is in the size range 1 nme100 nm.
By derogation from this deﬁnition, fullerenes, graphene ﬂakes and single-wall carbon
nanotubes with one or more external dimensions below 1 nm are considered
as ‘substances at nanoscale’.”
All Regulatory Deﬁnition
Taiwan Council of Labor Affairs
(Taiwan, 2012)
A nanomaterial is one which is intentionally manufactured or designed and meets
any of the following conditions:
A) Material with one or more external dimensions or an internal or surface structure
on the scale from 1 to 100 nm;
B) It is smaller or larger than the nanoscale above in all spatial dimensions and exhibits
one or more nanoscale phenomena/property (for example, increased intensity and
chemical reactivity).
C) 13 engineered nanomaterials by OECD in 2010 which can be used as reference
are provided in the deﬁnition.
All Advisory Deﬁnition
Swiss Federal Ofﬁce of Public
Health and Federal Ofﬁce
for the Environment
(H€ock et al. 2013)
Utilizes European Commission, Recommendation on the Deﬁnition of Nanomaterials
(EC, 2011), but also includes particles up to 500 nm and respirable particles of up to
10 microns with nanoscale side chains.
All Advisory Deﬁnition
Norwegian Environment
Agency (2014)
Follows the European Commission, Recommendation on the Deﬁnition of
Nanomaterials (EC, 2011)
All sectors, but
only for chemicals
classiﬁed as hazardous
according to stated
criteria.
Regulatory Deﬁnition
Belgian Federal Public Service
Health, Food Chain Safety
and Environment
(Belgium, 2014)
“Substance produced in nanoparticular state” is deﬁned as a substance containing
unbound particles, or aggregate or agglomerate of those particles, where 50% or more
of the particles in the number size distribution have one or more external dimension
is in the size range of 1e100 nm. The deﬁnition excludes natural, non-chemically modiﬁed
substances and those for which the fraction in the 1e100 nm range is “a byproduct
of human activity,” which is further deﬁned.
Scope is deﬁned by
a complex set of
exemptions.
Regulatory Deﬁnition
Danish Ministry of the
Environment (2014)
Follows the European Commission, Recommendation on the Deﬁnition of Nanomaterials
(EC, 2011)
Scope is deﬁned by
a complex set of
exemptions.
Regulatory Deﬁnition
D
.R.Boverhof
et
al./
Regulatory
Toxicology
and
Pharm
acology
73
(2015)
137
e
150
140
Table 2
Comparative assessment of elements considered in current regulatory and advisory deﬁnitions of “nanomaterial”.
Organization and/or regulation Size Solubility Aggregates and
agglomerates
Distribution threshold Intentionally
manufactured/
engineered
Novel
properties
European Commission Cosmetics Directive 1e100 nm Yes Yes No speciﬁc mention Yes No
Australian Government Department of Health and Ageing 1e100 nm No Yes 10% by number Yes Yes
Health Canada 1e100 nm and largera No Yes No speciﬁc mention Yes Yes
United States Food and Drug Administration 1e100 nm and largerb No No speciﬁc
mention
No speciﬁc mention Yes Yes
United States Environmental Protection Agency 1e100 nm No Yes 10% by weight Yes Yes
European Commission Recommendation for a Deﬁnition 1e100 nm No Yes 50% by number No No
European Parliament and the Council of the European
Union on the Provision of Food Information to Consumers
1e100 nm and largera No Yes No speciﬁc mention Yes Yes
European Commission Biocides Directive 1e100 nm No Yes 50% by number No No
French Ministry of Ecology, Sustainable Development,
Transport and Housing
1e100 nm No Yes 50% by number Yes No
Taiwan Council of Labor Affairs 1e100 nm and largera No No speciﬁc
mention
No speciﬁc mention Yes Yes
Swiss Federal Ofﬁce of Public Health and Federal Ofﬁce
for the Environment
1e100 nm and largerc No Yes 50% by number No No
Norwegian Environment Agency 1e100 nm and larger No Yes 50% by number No No
Belgian Federal Public Service Health, Food Chain Safety
and Environment (Belgium, 2014)
1e100 nm No Yes 50% by number Yes No
Danish Ministry of the Environment (2014) 1e100 nm No Yes 50% by number No No
a Health Canada, the European Commission (for food and food contact materials) and the Taiwan Council of Labor Affairs have indicated the inclusion of materials larger
than the nanoscale in all dimensions if they exhibit one or more nanoscale properties/phenomena.
b The US FDA includes materials up to one micron if the material exhibits properties or phenomena that are attributable to its dimensions.
c The Swiss deﬁnition includes substances with primary particles, aggregates and agglomerates up to 500 nm, as well as respirable materials of up to 10 microns that may
have nanoscale side branches.
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the additional criteria discussed below.
3.2. Distributional thresholds and mass vs. particle number
An additional practical aspect of understanding how size deﬁnes
a nano-object or nanomaterial is the size distribution around a
median or mean. Few particulate substances are “monodisperse”
(i.e., with a geometric standard deviation <2). Instead, most natu-
rally occurring and manufactured nanomaterials have size distri-
butions that may vary widely. Fig. 1A shows the hypothetical
distribution of two particle populations with the samemedian size.
For these two examples, the distribution varies greatly, but most of
the particles are still in the nanoscale (less than 100 nm). However,
if only a portion of the particles in the distribution is within the
nanoscale, should that substance be considered a nanomaterial?
Fig. 1B illustrates a particle size distribution in which only 10% ofA B
Fig. 1. Particle size distribution considerations. (A) Hypothetical size distribution of two si
distributions. (B) A hypothetical particle size distribution highlighting that a substance w
population less than 100 nm.the particles fall within the nanoscale. Inclusion of a distributional
size cut-off as a component of a deﬁnition is needed to provide
increased clarity as to what should be considered a nanomaterial
(Bleeker et al., 2013). Many deﬁnitions include particle size distri-
bution as an important consideration, though inconsistently. Some
deﬁnitions deﬁne the particle size distribution based on the weight
percentage, while others deﬁne it based on the number count
distribution. For example, the European Commission has suggested
particle number count of 50%, whereas US EPA has suggested
>10% by weight (Table 2).
While the number count approach may seem intuitive when
speaking of particulate substances (Bleeker et al., 2013), the weight
percent approach is more consistent with current detection capa-
bilities and sensitivity of relevant analytical instrumentation, as
well as current practices for toxicological evaluations and estab-
lishment of occupational exposure limits. Current nanoparticle
metrology standards have been largely focused on mass andmple particle populations with the same mean particle size but different overall size
ith a mean particle size greater than 100 nm may still have a portion of the particle
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validate particle count distributions that go below 100 nm (Brown
et al., 2013). Despite this limitation, it has been noted that a focus
on mass or volume as part of a distributional threshold may result
in larger particles skewing the distribution and an overall under-
estimate of the true size distribution (Bleeker et al., 2013). Such a
situation would be most applicable for non-homogenous or multi-
modal populations of particulate substances and could be
addressed by speciﬁc analysis guidance. It is also true in that a
distribution based on particle number will skew the distribution
toward the smallest particles. While number count may be more
inclusive in terms of deﬁning substances as nanomaterials, the lack
of analytical approaches and examples of how it can be applied
effectively does not allow for an evaluation of the true utility of
such an approach. Using a number count criterion may result in the
inclusion of materials that have mass-based distributions much
greater than 1000 nm and would never be intended for inclusion as
part of a discussion of nanomaterials. For example, under the Eu-
ropean Commission's recommendation for a deﬁnition (EC, 2011a),
which includes particulates having 50% of particles by number
below 100 nm, millimeter sized ball bearings containing a trace
amount of sub-100 nm wear debris could be classiﬁed as a nano-
material, whereas a population of relatively monodisperse particles
with a median diameter of 110 nm may not meet the deﬁnition
(Brown et al., 2013). Issues with contamination have also been
highlighted with air, water, and even laboratory vessels where sub-
100 nm particles may be present in low mass but high numbers
(Brown et al., 2013). These examples illustrate how a deﬁnition
based on a number count distribution cut-off may result in the
inappropriate identiﬁcation of materials, which could impact the
practical implementation of such an approach.
Arguments for using particle number-based cut-offs in nano-
material deﬁnitions are based on the concept, supported by some
experimental ﬁndings over a number of years, that biological ef-
fects caused by particulates tend to correlate more closely with the
administered dose expressed as particle number or total surface
area rather than as mass (Tsuji et al., 2006; Wittmaack, 2007).
However, examination of the more recent literature reveals
differing opinions on the appropriate dose metric for describing the
biological or toxicological effects of nanomaterials. Data have been
presented to show that doseeresponse relationships with nano-
materials can be appropriately deﬁned by particle mass or volume
(Pauluhn, 2009, 2010). Other studies have suggested that total
particle surface area may be an appropriate metric (Stoeger et al.,
2006), while others have suggested that mass or surface area can
be effective descriptors depending on the material (Ho et al., 2011).
Another consideration for selection of the dose-metric is the
intended use of the dose characterization. For comparison of dose
within a given particle type and size, any of the dose-metric options
would likely be sufﬁcient. However, there is still uncertainty about
the toxicologically relevant dose-metric when comparing dose
across classes of particle types and size range. In these cases, it has
been suggested that particle numbers or surface area may be the
relevant choice (OECD, 2012).
Interestingly, in the area of occupational exposure limits, dis-
cussions on particle number versus mass measurements have
previously been addressed, and it was recognized that the use of
mass would be more relevant to deﬁning the health hazard while
providing a simpler, less expensive, and more reproducible method
than a particle count approaches (Tomb and Haney, 1988). In
addition, a recent workshop on occupational exposure limits (OELs)
for nanomaterials indicated that mass-based sampling and related
analytical methods are viewed as the most practical means for
routinely monitoring airborne particulates in the workplace
(Gordon et al., 2014). These factors are expected to drive OELdevelopment for nanomaterials towards mass-based measurement
values.
The analytical challenges of determining whether a material
meets the particle number-based EC deﬁnition have been recently
reviewed, the primary obstacle being the lack of standardized,
validated methods (JRC, 2014). Speciﬁc technical challenges of
number-based particle analyses identiﬁed in the JRC report include:
sample preparation techniques which can change the size distri-
bution; obtaining representative samples; counting primary par-
ticles within aggregates; determining the adequacy of dispersion
methods for powder; choosing the most appropriate size metric for
non-spherical particles (e.g., minimum external dimension, equiv-
alent sphere, etc.); and suitability of standard reference materials.
Other obstacles include the lack of interlaboratory proﬁciency
testing to identify laboratories which can reliably assess whether a
material is a nanomaterial according to the EC deﬁnition and the
high costs of performing these determinations, especially when
electron microscopy is required.
Until this issue is resolved, some have recommended that
toxicological studies of nanomaterials include the characterization
of particles in a manner that allows for conversions between
different metrics. While this may seem reasonable, it is important
to recognize that laboratory instruments used to measure particle
mass or volume often employ mathematical conversions to derive
particle count information and that, for these instruments, a 1%
error in the ability of a method to accurately describe a mass or
volume distribution at the nanoscale could translate to a greater
than 50% error in a number distribution (Linsinger et al., 2012;
Brown et al., 2013). Opinions from the Organization for Economic
Cooperation and Development (OECD) also recognize that it is
appropriate and likely that dose results will continue to be reported
in mass-based units and that any deviation from this might have
major consequences for the international mutual acceptance of
data and would impact classiﬁcation and labeling where hazards of
substances are related to mass concentration (OECD, 2012).
Based on these considerations, a mass-based distributional
threshold is considered more appropriate than a number-based
threshold. As with the 100 nm cut-off used for deﬁning nano-
objects in general, the choice of a weight percent cut-off such as
10% is considered a reasonable distributional cut-off that will
effectively capture materials of the size range that have been the
subject of nanotechnology discussions within various agencies and
organizations, while at the same time providing increased clarity
for manufacturers and users as to which materials should be
included and brought forward for discussion. A 10% weight cut-off
is also consistent with the resolution of many of the analytical
methodologies that currently exist for particle characterization
(Linsinger et al., 2012; Brown et al., 2013), which will help with the
application of deﬁnitions. As analytical resolution increases and our
collective understanding of the biological and toxicological impli-
cations of nanomaterials improves, cut-offs such as 100 nm and 10%
by weight may change. In the meantime, the use of these limits
allows for a consistent and conservative approach for the assess-
ment of nanomaterials.
3.3. Aggregates and agglomerates
Manufacturing processes can have an important impact on the
form of particulates and how particles may associate with one
another. Nanomaterials are produced by either “top down” or
“bottom up” manufacturing approaches (Luther, 2004). Most con-
ventional nanomaterial manufacturing processes are “top down” in
which a larger sized material is ground or milled to smaller particle
sizes. Depending on the amount of energy applied in the process,
the ﬁnal material may range in size from micronscale to nanoscale.
Fig. 2. Considerations for primary particles, aggregates and agglomerates. (A) A bottom-up synthesis approach for synthetic amorphous silica through a pyrogenic process. The
process involves hydrolysis of volatile silanes, such as silicon tetrachloride (SiCl4), in the ﬂame of an oxygenehydrogen burner. This results in the growth (nucleation, condensation,
coagulation) and aggregation of pyrogenic silica particles. Tightly bound aggregates can then form agglomerates of aggregates. Reprinted from Synthetic Amorphous Silica (CAS No.
7631-86-9)” JACC No. 51, September 2006, p. 45.©2006, with permission from European Centre for Ecotoxicology and Toxicology of Chemicals. (B) Relationship of primary particle,
aggregates of primary particles, agglomerates of primary particles, and agglomerates of aggregated primary particles.
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down”method, inwhich graphite is mechanically reduced in size to
“sheets” of graphene having nanoscale dimensions (Knieke et al.,
2010). Pigments are another example of nanomaterials that are
commonly produced by a top down approach.
By contrast, nanomaterials produced by “bottom up” processes
are synthesized from atomic or molecular species by chemical re-
action(s), allowing the precursor particles to grow in size. Solegel
chemistry is an example of this approach in which solid nano-
particles dispersed in a liquid (a solution or sol) agglomerate to
form a continuous three-dimensional network extending
throughout the liquid (a gel) (Young, 2002). Thin ﬁlms and xerogels
are examples of nanomaterials produced by the solegel process
(Brinker et al., 1992; Dur~aes et al., 2012). Another type of “bottom
up” nanomaterial manufacturing involves high temperature com-
bustion of chemical feedstock to produce airbornemolecules which
immediately collide to form solid nuclei. During this process,
coagulation rates are very rapid, with nuclei sintering or coalescing
into spherical primary particles (also called “nodules”). Within
milliseconds, the primary particles coalesce (sinter) into larger
particles, called aggregates. As the manufacturing process con-
tinues, the aggregates collide, resulting in secondary structures,
known as agglomerates (Donnet et al., 1993). Industrial aciniform
aggregates (e.g., titanium dioxide, carbon black and some forms of
synthetic amorphous silica) are examples of nanostructured ma-
terials produced by thermal combustion processes. Fig. 2A illus-
trates the production of aggregated and agglomerated substances
manufactured by a bottom-up high temperature combustion
process.
The manufacturing processes described above can produce
three different forms of particulates which may exist at the nano-
scale: discrete primary particles, aggregates, and agglomerates. Key
properties of each form are discussed below and depicted in Fig. 2B.
ISO deﬁnes a “particle” as a minute piece of matter with deﬁned
physical boundaries (ISO, 2008). Primary particles are considered
the smallest discreet entity. Theymay exist at the nanoscale and areconsidered to be an indivisible entity. ISO deﬁnes an “aggregate” as
a particle comprised of strongly bonded or fused particles where
the resulting external surface areamay be signiﬁcantly smaller than
the sum of calculated surface areas of the individual components.
Aggregates may be comprised of constituent primary particles that
range in size from nanoscale to greater than 100 nm and,
depending on the size and number of the primary particles, ag-
gregates themselves can range in size from the nanoscale to
micronscale. It is the size and shape of the aggregates that have a
fundamental inﬂuence on the properties of the nanomaterial
(Donnet et al., 1993). Importantly, aggregates are robust, essentially
indivisible structures, similar to primary particles, in that they
cannot be broken down by external forces typically encountered
during subsequent handling and processing (Gray and Muranko,
2006). In contrast, an “agglomerate” is a collection of weakly
bound particles, or aggregates ormixtures of the two, and for which
the resulting external surface area is similar to the sum of the
surface areas of the individual components (ISO, 2008). Agglom-
erates are held together by relatively weak forces, such as van der
Waals forces or by simple physical entanglement. Therefore, in
contrast to aggregates, agglomerates may break down into their
constituent entity(s) with sufﬁcient external energy (Donnet, 1993;
Gray and Muranko, 2006). Agglomerates themselves can vary in
size but are typically greater than 100 nm.
Most deﬁnitions speciﬁcally include aggregates and agglomer-
ates (Tables 1 and 2). Although aggregates and agglomerates can be
much larger than 100 nm, many deﬁnitions include these entities
based on consideration of the potential for these structures to break
down into smaller nanoscale entities if sufﬁcient force is applied.
The EU Commission's recommendation on the deﬁnition of a
nanomaterial notes “agglomerated or aggregated particles may
exhibit the same properties as the unbound particles (EC, 2011a).
Moreover, there can be cases during the life-cycle of a nanomaterial
where the particles are released from the agglomerates or aggre-
gates.” This concern merits scientiﬁc examination. Gray and
Muranko (2006) investigated the robustness of two different
Fig. 3. Pulmonary clearance of inhaled particulates. Pulmonary clearance of particles
can be achieved through dissolution or mechanical clearance which can impact the
overall toxicity of the material. Mechanical clearance includes particle transport by
mucocilliary activity (primarily upper respiratory), phagocytosis by macrophages and
migration via the mononuclear phagocyte system, or direct translocation of particles
though respiratory epithelium.
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by evaluating the mechanical forces needed to break down the
aggregate structure. They concluded that despite the extreme
processing of aggregate materials, there was no signiﬁcant libera-
tion of nodules (primary particles), although there was some
reduction in size of aggregates by internal fracture. The fracturing
was reported to occur at weak spots in the necks between nodules.
Continued application of mechanical energy did further reduce
aggregate dimension once the weak necks had been fractured.
Thus, in the aggregate materials studied, the fusing together of
primary particles within aggregate structures is tight and strong
and therefore the aggregates represent robust discreet particulates.
The authors further concluded that aggregate structures that are
able towithstand these intensemechanical forces are unlikely to be
broken down in a biological system in which forces are very weak
by comparison.
This conclusion is supported by the work of Maier et al. (2006)
who investigated whether lung surfactant may promote disaggre-
gation of titanium dioxide particles. They evaluated whether the
energy of interaction between the main component of lung sur-
factant and titanium dioxide is sufﬁcient to split the bonds between
primary particles of titanium dioxide aggregates and/or the bonds
between aggregates of titanium dioxide agglomerates. Using
mathematical modeling, they determined that the interaction en-
ergy is insufﬁcient to split the bonds. To validate the mathematical
model, the authors measured the particle size distribution of tita-
nium dioxide suspensions in simulated lung ﬂuid over time and
found no appreciable change in the particle size distribution,
indicating that the titanium dioxide did not break down in the
simulated lung ﬂuid. The authors conclude that lung surfactant
does not promote the disaggregation of titanium dioxide aggre-
gates or agglomerates.
Using various exposure modes (i.e. intratracheal instillation and
the inhalation of aerosols with nano-sized or microsized particles),
Creutzenberg et al. (2012) investigated the fate of nanoparticle
agglomerates after uptake in the lung and found a tendency of
nanoscale particles to form larger size agglomerates following
deposition and interaction with cells of the respiratory tract. The
authors concluded that an increase in particle number due to a
disintegration of agglomerates does not seem to be of high bio-
logical relevance.
Less work has been done in environmental systems, but the
results found in mammalian studies are generally applicable to
environmental media. The energy found in environmental settings
is not sufﬁcient to break apart aggregates, though it has been
demonstrated that agitation in combination with surfactancy and
contributions to ionic strength provided by natural organic matter
can cause some agglomerates to break apart (Brant et al. 2005; See
also Taurozi et al., 2011).
Overall, given the current scientiﬁc literature, the inclusion of
aggregates and agglomerates in a regulatory deﬁnition may not
always be warranted. Speciﬁcally, aggregates that have been shown
not to break down into smaller forms under normal industrial
processing or anticipated use conditions should not be treated as
discreet nanomaterials for assessment purposes. These aggregates
may have biological properties that are effectively represented by
larger-scale or bulk forms of the same material. These concepts
should be considered in the overall identiﬁcation and assessment of
nanomaterials and will be important in read-across assessments.
3.4. Solubility
Solubility in biological and ecological media is another impor-
tant consideration in the evaluation of nanomaterials because it
helps distinguish between characteristics of the material that arebased on molecular identity alone and characteristics that are
inﬂuenced by particle behavior, such as surface activity. Most cur-
rent deﬁnitions do not consider solubility although the importance
of solubility is recognized in the global guidance document from
the International Council on Cosmetic Regulations (ICCR) (Rauscher
et al., 2012) and is incorporated into the European Commission
Cosmetics Directive deﬁnition (EC, 2009).
Solubility has not been explicitly deﬁned for nanomaterials.
Without a fundamental deﬁnition of solubility to identify which
nanomaterials would be soluble and which would not, a practical
approach may be to use existing guidelines of classifying solubility
such as used by the EC's Scientiﬁc Committee on Consumer Safety
(SCCS) in their Guidance on the Safety Assessment of Nano-
materials in Cosmetics (SCCS, 2012). Using this approach, poorly
soluble materials are classiﬁed as having an aqueous solubility of
less than 1 mg/L. The corollary of that would be substances equal to
or greater than 1 mg/L would be considered soluble.
Rapid dissociation of particles to ions or molecules would
indicate that the toxicology of the particle (and the assessment of
risk) should be based primarily on the molecular identity
(SCENIHR, 2007) rather than properties of the particle (surface
reactivity or crystallinity, for example). The properties of materials
that quickly dissociate in biological or ecological ﬂuids are likely to
be dominated by the properties of the molecular and/or ionic form.
They will be absorbed, distributed, and eliminated as the molecular
form, while those that dissociate slowly will primarily behave as
particulates. For example, zinc oxide and cadmium selenide
(quantum dots) particles have been shown to dissociate into ions
(Hardman, 2006; Xia et al., 2008; Gulson et al., 2010; Galeone et al.,
2012), and the dissociated ions thereby contribute to the biological
properties of the particles. When considering solubility for regu-
latory purposes, the kinetics of dissolutionwill be important rather
than total solubility at equilibrium. The rate of solubility will
determine the amount and form of substance available for possible
biological activity from the time thematerial is inhaled towhen it is
cleared. While a less common phenomenon, it should be noted that
for some materials, nanoparticles can form from dissolved species
under ecological conditions (Slowey, 2010; Akaighe, 2011).
The relationship between dissolution and mechanical clearance
mechanisms has been well studied and shown to be important for
predicting the biological effects of inhaled particulate and man-
made ﬁbers (Fig. 3) (Oberd€orster, 1989; Davis, 1994; Oberd€orster
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includes particle transport bymucocilliary activity (primarily upper
respiratory), phagocytosis by macrophages and migration via the
mononuclear phagocyte system, or direct translocation of particles
though respiratory epithelium. As an example, consider the dif-
ference in potential biological effects between three nanoscale
materials: sea salt (NaCl), zinc oxide (ZnO) and titanium dioxide
(TiO2). The salt will dissociate almost instantly upon inhalation and
contact with the mucosa. The pattern of dissociation of ZnO par-
ticles is more complex but eventually leads to some proportion of
solubilization (Lopes et al., 2014), while the nanoscale TiO2 is
essentially insoluble with a half-life of weeks in the lung
(Oberd€orster et al. 1994, Bermudez et al. 2004). The clearance of
inhaled particulate NaCl begins with rapid dissolution followed by
absorption and elimination of the solubilized ions. Clearance of ZnO
is initially by a combination of mechanical means and through
dissolution, while TiO2 clearance is almost exclusively by me-
chanical means due to its limited solubility in biological ﬂuids
(Bermudez et al., 2004). The physical form of the sea salt exposure
is largely unimportant to the biological effects since it is immedi-
ately dissociated into its ionic components while the effects of the
TiO2 will be determined primarily by its physical form. The po-
tential effects of inhaled ZnO will be a mix of particle effects
(initially) and the effects from the ionized form of Zn produced by
the dissolution. Thus, the consideration of solubility and dissolution
rate is important in distinguishing between materials that have the
potential for displaying size-dependent particulate effects and
those materials whose effects are due to the molecular form
regardless of their initial physical particulate form.
Factors that affect dissolution include composition of the me-
dium, ionic strength, temperature, pH, and the presence of ligands,
such as proteins, lipids, or formed elements in the blood, that can
preferentially bind to the nanomaterial and shift the kinetics of
clearance (Rauscher et al., 2012). Surface architecture, coatings, and
agglomeration state also inﬂuence dissolution (Borm et al., 2006;
Rauscher et al., 2012). Thus, evaluating the extent and rate of
dissolution is not trivial. Unfortunately, there are no standards for
deﬁning solubility relative to the rate of dissolution. Categorical
statements such as “insoluble” have little meaning for solid parti-
cles. Indeed, there is little agreement about what soluble/insoluble
and slow/rapid clearance mean with reference to inhaled particles.
For example, amorphous silica has a half-life in the lungs of rats of
around 50 days yet it is said to be cleared “rapidly” mainly by
“dissolution” in lung ﬂuid (Fruijtier-Polloth, 2012). Instead, the rate
of dissolution may be more valuable in characterizing whether a
particle remains intact or dissociates into components that may
drive further assessment.
Because the biological effects of materials that rapidly dissolve
in biological ﬂuids are primarily related to their chemical properties
and not their physical form, they would not appear to warrant
additional regulatory interest beyond that given to the non-nano
form of the same materials. Presumably, larger-scale soluble
inhaled particles will pass through the nanoscale size range as they
dissolve and would exhibit the biological effects relevant to the
nanoscale form. Thus, the toxicological information from the larger
particles may also be relevant to the toxicology of the nanoscale
form. Ultimately, solubility and dissolution are important factors
that need to be considered in the assessment of nanomaterials.
3.5. Intentionally manufactured nanomaterials
Nanoscale particles are not new to nature. They have been
ubiquitous from the formation of the earth to the present, and we
are constantly surrounded by nanoparticles. For example, the air
we breathe contains tens of thousands of nanoparticles per cubiccentimeter (Buzea et al., 2007; Hochella et al. 2008; Slezakova et al.
2013). Some of these nanoparticles are incidental particulates of
man-made origin such as combustion products from the burning of
coal and petroleum products, residues from abrasion, and even
baking. Many others are of natural origin, coming from weather,
volcanic dust, sea spray, and natural combustion sources such as
forest ﬁres. The volume of naturally occurring nanomaterials far
exceeds the volume of those produced from man-made sources
(Buzea et al., 2007). While it is recognized that some very small
particles can cause health concerns due their composition and/or
concentration in air, more than the simple presence of very small
particles is needed to focus attention on these materials.
We recommend that a core element of any deﬁnition for
nanomaterials in commerce include only those nanomaterials that
are intentionally manufactured (i.e., engineered). Inclusion of this
element would avoid inappropriate focus on nanomaterials that are
produced incidentally and those from natural sources, allowing
stakeholders to focus on materials that are intentionally manu-
factured at the nanoscale to have speciﬁc properties. ISO (2010)
provides useful deﬁnitions for two types of nanomaterials, manu-
factured and engineered. A manufactured nanomaterial is inten-
tionally produced for commercial purposes to have speciﬁc
properties or speciﬁc composition (e.g., transparency). An engi-
neered nanomaterial is designed for speciﬁc purpose or function
(e.g., quantum dots).
In each case, the intent of manufacturers is to take advantage of
properties the nanomaterial provides based on its size. Hence it is
appropriate to consider intentional manufacture as a core element
in the assessment of the nanomaterial. Most current deﬁnitions
include this important element (Table 2), but we believe it is one
that should be adopted uniformly.
3.6. Size-dependent properties of nanomaterials
Nanomaterials are typically developed and used to take
advantage of size-dependent properties that do not exist for com-
parable materials of larger sizes and are therefore considered un-
usual or novel. For some nanomaterials there are properties that
are size-dependent and are not easily predictable based on the
properties of larger forms of the same material. From Auffan et al.
(2009), examples include:
 The melting point of tin is 232 C when its particle size is
>100 nm but at a particle size of 6 nm, its melting point is only
14 C.
 Cadmium selenide is normally a semiconductor, but when
formed into a 5e10 nm quantum dot the movement of electrons
is much more limited (quantum conﬁnement) resulting in the
generation of intense size-dependent visible light emissions
(ﬂuorescence) of a narrow band of wavelengths (color) when
excited by less intense white or blue light.
 Gold is generally considered to be chemically inert, making it an
ideal material in many applications such as electronic connec-
tions and jewelry. Interestingly, gold becomes catalytic when its
particle size is reduced to the nanoscale.
In contrast, many nanomaterials do not exhibit unusual or novel
properties when compared to their larger scale forms. An example
of a size-dependent property that is not unusual is a change in
surface area compared to mass. This property is easily determined
both analytically andmathematically, and, for a givenmass, smaller
particles have more surface area than larger particles. An applica-
tion of this property is in absorption, where high surface area solid
materials can be used to absorb more liquid than a comparable
amount of low surface area material. Another example is in
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strengthening agents in plastics, and smaller sized materials pro-
vide more strength for a given mass than larger particles. As noted,
this property is size-dependent but is not novel or unusual (Fu
et al., 2008).
From an assessment standpoint, the important issue is whether
the nanomaterial has biologically relevant size-dependent prop-
erties that differ from those of the same material at a larger scale
and which make read-across of toxicological data from the larger
material questionable. Some size-dependent properties may have
little or no relevance for hazard identiﬁcation (e.g., melting point,
color), while others may be highly relevant (e.g., surface area ac-
tivity, solubility). Therefore, we recommended that nanomaterial
evaluation frameworks focus on nanomaterials that have unusual
(i.e., not readily predictable) size-dependent properties that may
merit additional review.
Many deﬁnitions already include the concept of “novel” or
“unique” properties or “nanoscale phenomena” (Tables 1 and 2).
However, most current deﬁnitions provide little or no guidance as
to which properties should be considered novel and unique for
hazard assessment purposes and fail to adequately consider the
difﬁculties entailed in accurately measuring these properties. For
example, surface reactivity is frequently mentioned as an impor-
tant contributing factor to the (eco)toxicity of nanomaterials.
However, there is no consensus on the most appropriate methods
for measuring surface reactivity, and available methods may be
prone to artifacts and misinterpretations (Horst et al., 2013;
Petersen et al., 2014). Some deﬁnitions include extension of these
unusual properties to materials greater than 100 nm in size, and it
is recommended that in these cases the deﬁnition guidance should
clearly indicate the basis for the inclusion of larger materials.
Overall, additional discussion and clarity in this area is critical to
ensure consistency and transparency in the identiﬁcation and
assessment of nanomaterials.
4. Discussion
Taken together, the elements discussed abovedparticle size, a
distributional threshold, intentional manufacture, the state of
agglomeration/deagglomeriation and aggregation/disaggregation,
solubility/dissolution rate and precipitation/reformation, and
relevant size-dependent propertiesdrepresent important compo-
nents that should be considered when discussing nanomaterial
deﬁnitions or establishing evaluation frameworks. Purely technical
nanomaterial deﬁnitions based only on particle size, such as ISO's
deﬁnition (ISO, 2008), are not useful from a safety evaluation
standpoint because they can include virtually every substance that
may exist in particulate form. Nanomaterial evaluation frameworks
should be established to help to narrow the scope to those nano-
scalematerials that maymerit additional evaluation for purposes of
protecting human health and the environment while at the same
time having appropriate clarity of scope and being practical to
implement.
Each of the elements discussed in this paper is included in one
or more of the deﬁnitions we reviewed; however, they are not used
consistently and often differ in the scope speciﬁed by a particular
element. As a result, a substance considered a nanomaterial under
one regulatory scheme may not be considered a nanomaterial in
another. Such inconsistency creates considerable difﬁculty for
nanomaterial manufacturers and users in complying with multiple
regulatory requirements and may lead to the perception among
customers and the public that nanomaterials are not being
adequately evaluated or regulated. As governmental authorities
consider moving forward with discussions on nanomaterial deﬁ-
nitions and risk evaluation frameworks, they should strive forgreater alignment and consistency in what is considered to be a
nanomaterial. Consistency will be instrumental for ensuring the
transparent identiﬁcation of materials that warrant additional
consideration, stakeholder conﬁdence in the current regulatory
frameworks, and continued development of nanotechnology.
It is also important to give adequate consideration to ongoing
developments in research that informs the human health and
environmental assessment of nanomaterials. Many of the initial
concerns regarding nanotechnology revolved around un-
certainties concerning the potential impact of nanomaterials on
human health and the environment. From a regulatory perspec-
tive, there were two key areas of concern: (1) whether hazard,
exposure, and risk assessment methods used for other materials
can be applied to nanomaterials, and (2) whether existing regu-
latory frameworks, which do not distinguish materials on the
basis of size, can ensure proper identiﬁcation, review, and regu-
lation of nanomaterials.
The ﬁrst concern about the applicability of hazard assessment
approaches for other materials was largely based on concerns that
nanomaterials might harbor unknown modes of toxicity or exhibit
nano-speciﬁc biological effects that would not be detected through
the use of current hazard evaluation approaches. Today there is an
extensive and growing body of research on nanomaterial toxicity
that addresses this concern. One of the most comprehensive efforts
has been implemented through the OECD, which launched a pro-
gram of work to ensure that the approaches for hazard, exposure,
and risk assessment are appropriate for the evaluation of nano-
materials (OECD, 2006). The methods and approaches considered
are applicable to human, animal, and environmental situations.
Preliminary conclusions from this work have indicated that current
approaches for the testing and assessment of traditional chemicals
are appropriate for assessing the safety of nanomaterials (OECD,
2009; OECD, 2012). It is acknowledged that certain test methods
may need to be adapted to allow for appropriate compatibility with
nanomaterials. This is in alignment with a recent perspectivewhich
indicated that there is no evidence that nanomaterials exhibit novel
mechanisms of toxicity and that conventional particle toxicology
data are useful for the determination of nanoparticulate hazard
potential (Donaldson and Poland, 2013). Such conclusions repre-
sent important advancements in our understanding of nano-
materials and should be considered as discussions on safety
evaluation and the need for deﬁnitions continue to evolve.
With respect to the second concern, the ability of current reg-
ulatory frameworks to ensure proper identiﬁcation and review of
nanomaterials, the OECD has recommended that its member
countries apply existing international and national frameworks to
manage any risks associated with the manufacture and use of
nanomaterials (OECD, 2013b). As part of its recommendation, OECD
notes that current frameworks may need to be adapted; however,
completely new frameworks are not needed for nanomaterials.
Efforts in the OECD are now focused on nanomaterial evaluation
approaches including those related to identiﬁcation, characteriza-
tion and read-across assessment approaches (OECD, 2013a).
While the discussion on elements of nanomaterials that may be
important for safety evaluation is important, we believe many
groups have focused on the development of deﬁnitions for identi-
ﬁcation of nanomaterials without consideration of how theywill be
used. If deﬁnitions are developed, they should be developed in
conjunction with plans for implementation. In this sense, demon-
stration of how deﬁnitions would be applied through the use of
case studies may be informative.Without such a parallel strategy, it
is difﬁcult to understand the true scope of the deﬁnition or how
speciﬁc elements of the deﬁnition can best be addressed, especially
considering the complex analytical characterization that may be
required.
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Commission recommendation (EC, 2011a), which states that the
recommendation should be used as a reference for determining
whether a material should be considered as a “nanomaterial” for
legislative and policy purposes. The Commission appears to
recognize that its recommendation should not simply be imple-
mented as written, but that individual regulationsmay have unique
requirements that a single, rigid deﬁnition may not satisfy. The
Commission also states that the identiﬁcation of a nanomaterial
should not prejudge or reﬂect the scope of legislation or provisions
for potentially establishing additional requirements for nano-
materials, including those relating to risk management. The Com-
mission goes on to state that in some cases it may be necessary to
exclude materials from the scope of any legislation even if they fall
within the deﬁnition (EC, 2011). These statements clearly indicate
that implementation of the deﬁnition as part of an evaluation
framework will require additional guidance and scope reﬁnement.
A recent example of the complexity associated with imple-
menting a regulatory deﬁnition can be seen with the French Reg-
istry for nanomaterials. The registry requires reporting of
nanomaterials marketed in France and leverages the European
Commission's recommended deﬁnition (ANSES, 2012). Imple-
menting the registry required extensive additional guidance
beyond the deﬁnition to determine what was within scope and
therefore reportable. Initial guidance was supplemented by
extensive question and answer documentation during the actual
reporting process. For example, one point of clarity focused on the
deﬁnition term “intentionally manufactured”whichwas to indicateFig. 4. Example approach for implementation of a nanomaterial deﬁnition into a regulato
authority and moves beyond identiﬁcation towards a framework for assessment. Importantly
evaluated to ensure that they are safe for their intended uses. While deﬁnitions may not in
presented in this paper (listed on the left of the ﬁgure) should be considered at some point d
review.the deliberate manufacturing of a substance at the nanoscale and
excluded nanomaterials that may be unintentional by-products of
the synthesis process. Another point of clarity was provided on the
lack of a need to declare a substance if it was bound in a mixture
from which it was not expected to be released or extracted under
normal or foreseeable conditions of use. This exclusion highlights
the consideration of release and/or exposure potential as part of the
framework for identiﬁcation of materials, which is an important
component in the evaluation of potential downstream risk. This
example represents the activity of a single country within the Eu-
ropean Union, but additional country-speciﬁc registries have been
implemented (Tables 1 and 2). Clearly, any variation on the use of
deﬁnitions and how they are implemented within and among
different regions can lead to inefﬁciency, inconsistency, and
miscommunication.
An additional example illustrating the challenge of a regulatory
deﬁnition comes from a proposed rule issued by the US Environ-
mental Protection Agency (US EPA, 2011a). The Agency proposed a
rule that sought to obtain information pertaining to the use of
nanomaterials in pesticide products. However, it was noted in one
of the public comments that the lack of clarity in how the Agency
deﬁned a nanomaterial at that time would make it difﬁcult for
those who develop pesticide products to know if their materials
were considered to be nanomaterials (ACC, 2011). The authors of
the response recommended that the Agency consider developing a
more clear deﬁnition using many of the concepts explained above.
These examples highlight the difﬁculty of implementing a
deﬁnition, which in turn provides support for considering thery decision framework. The framework starts with the deﬁnition from the regulatory
, regardless of the deﬁnition used, all substances and materials should be appropriately
corporate all of the elements that are described above, we believe that the elements
uring the evaluation process to determine if the material requires additional regulatory
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ment process. Implementation of a deﬁnition without integration
into a regulatory framework results in the identiﬁcation of a list of
materials without purpose or action, which could lead to unnec-
essary stigmatization of nanomaterials as a whole. The potential for
formation of such perspectives is well-recognized and speciﬁcally
highlighted as an area of concern within a White House memo-
randum on regulatory frameworks for nanomaterials (Holdren,
2011). The memorandum notes that agencies should avoid mak-
ing unfounded generalizations that categorically judge nano-
materials as intrinsically benign or harmful. Importantly,
nanomaterials are not inherently hazardous, and therefore deﬁni-
tions and frameworks that intend to identify nanomaterials should
be established to avoid such generalizations and avoid establishing
nanomaterial inventories without purpose. Even for those nano-
materials for which health or environmental hazards have been
identiﬁed, it is important to recognize that the actual health or
environmental risk will be determined by the potential for expo-
sure to the material. The concept of considering both hazard and
exposure as a determination of risk is inherent in the regulatory
process and should be maintained for the assessment of
nanomaterials.
Ultimately, if a deﬁnition or deﬁnition system for identifying
nanomaterials is needed, its application within the current
assessment framework should be addressed. An example of how a
nanomaterial deﬁnition can be incorporated into a risk-based
assessment framework is presented in Fig. 4. The ﬁrst step is to
determine whether the substance falls into the scope of interest for
nanomaterials. If a material meets the criteria for a potential
nanomaterial (which may be speciﬁed by certain deﬁnition ele-
ments), the next step should be to determine whether it is a new or
existing chemical substance according to the applicable regula-
tions. If the nanomaterial is a new substance, the manufacturer or
importer must follow the standard notiﬁcation and registration
process to ensure that the nanomaterial undergoes regulatory re-
view. Registrations of new nanomaterials should include available
information that may be relevant to the evaluation of potential
hazards and risks.
If the nanomaterial is considered an existing chemical substance
under the applicable regulations, the next level of assessment
should be to determine whether existing toxicology and/or safety
data for the nanomaterial (or the larger form of the same material)
are available and adequate for assessing potential human health or
environmental risks under anticipated or foreseeable exposure
scenarios. Examples of existing nanomaterials for which robust
toxicology datasets are available include carbon black, synthetic
amorphous silica, and zinc oxide, all of which have been used for
decades and evaluated in numerous toxicological and epidemio-
logical studies. The potential risks and appropriate safe handling
practices for these so-called “historical” nanomaterials are well
understood. Except in unusual cases (e.g., a previously untested
route of exposure), additional regulatory review of these nano-
materials would seem to offer little added value and divert scarce
resources. This concept is consistent with existing perspectives that
some materials should be excluded from any developing nano-
material legislation (EC, 2011).
If the nanomaterial does not have a speciﬁc toxicological data
set sufﬁcient for evaluating potential risks, the next consideration is
whether the nanoscale material possesses novel size-dependent
properties relative to larger forms of the same material and, if so,
whether such properties could plausibly inﬂuence the hazard/
exposure/risk proﬁle of the nanomaterial relative to its larger
forms. As discussed previously, some nanomaterials do not possess
novel size-dependent properties (i.e., ones not readily predictable
based on simple size scaling), and some novel properties (e.g., colordifferences observed at the nano-scale) have no known or plausible
correlation to hazard or risk. Additional elements could also be
considered at this stage (if not previously addressed as part of the
scoping stage), including solubility/dissolution and impact of ag-
gregation/agglomeration. Doing so provides an opportunity to
evaluate the material with consideration of the ability to use read-
across approaches to predict the hazards/risks of the nanomaterial
based on available information from the larger-scale material. As
noted previously, the size boundaries for deﬁning nanomaterials
are arbitrary, and many material properties are predictable and
scalable as their size decreases from >100 nm to smaller sizes. On
the other hand, if a nanomaterial possesses novel size-dependent
properties that could plausibly inﬂuence hazard or risk, read-
across from the larger-scale material may be inappropriate, and
additional information on the nanomaterial should be gathered or
generated.
Throughout this proposed approach and regardless of the deﬁ-
nition used, it is critical at each stage of the evaluation process to
ensure conﬁdence in the hazard and risk assessment of the sub-
stance, consistent with good product stewardship and the princi-
ples of Responsible Care®, to ensure that all substances are safe for
their intended use (ACC, 2014; ICCA, 2014). Furthermore, it is
acknowledged that more detailed guidance than that presented
here will be necessary as part of a nanomaterial evaluation
framework, regulatory or otherwise (e.g., Environmental Defense
Fund and DuPont, 2007; Oomen et al., 2014). While emerging
deﬁnitions may not incorporate all of the elements that are
described above, we believe that the elements presented in this
paper should be considered at some point during the evaluation
process to determine if the material requires additional review.Transparency document
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